The real problem holding back connected vehicle programmes

Tern plc

Automakers are pushing hard to deliver software-defined vehicles with full over-the-air functionality. But many programmes are hitting delays and complications that have little to do with software quality or hardware design. The problem is identity, specifically, how manufacturers handle cryptographic keys, certificates, and trust across every electronic component and software process in the vehicle.

This used to be a security issue. Now, it is a production and operations issue, directly affecting rollout speed, servicing, and regulatory compliance. As vehicles become more connected and updates more frequent, identity management is turning into a core constraint that affects timelines and scale. Automotive platforms are struggling to keep cryptographic assets consistent across multiple suppliers, regions, and ECU generations. That inconsistency can block updates, break rollback mechanisms, and prevent legitimate servicing.

The UN’s WP.29 cybersecurity requirements, together with ISO 21434 and upcoming legislation like the EU Cyber Resilience Act, are putting formal pressure on OEMs to prove their vehicles are secure, traceable, and tamper-proof throughout their lifetime. Even authorised servicing now demands stricter identity and access control, forcing manufacturers to rework how they handle keys and certificates from factory to workshop.

Device Authority is one such company helping OEMs manage identity at scale. Its platform supports automated certificate provisioning, policy enforcement, and compliance tracking across ECUs, software components and servicing tools.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search